Statistics from Altmetric.com
Recombinant interferon alpha (IFN2B) is a proposed therapy for corneal intraepithelial neoplasia (CIN). Clinical response to this treatment is frequently challenging due to the delay between initiation of the IFN2B topical application and the beginning of CCIN regression. We present the case of a successful IFN2B treatment with prospective in vivo confocal microscopy imaging.
A 50-year-old man was referred to our department for a recurrence of a conjunctival–corneal intraepithelial neoplasia (CCIN) in his right eye. A 2-month course of topical 0.02% mitomycin C (MMC) therapy was withdrawn a month earlier due to lid allergy. The lesion extended nasally from conjunctiva to peripheral cornea. Despite a surgical excision with cryotherapy, the intraepithelial neoplasia recurred 1 month later in the peripheral cornea (figs 1, 2). Since the large limbal resection and MMC treatment presented the risk of corneal epithelial stem cell deficiency, IFN2B was chosen as a subsequent therapeutic procedure.1 The follow-up included slit lamp and in vivo confocal microscopy examination on a monthly basis during 6 months. Under this regimen, healing was observed within …
Competing interests None.
Ethics approval Ethics approval was provided by Paris University (XV–XX).
Patient consent Obtained.
Provenance and Peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.